Check-Cap Ltd. (MBAI)
NASDAQ:MBAI
Want to see MBAI full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Check-Cap (MBAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.43M
Dividend YieldN/A
Average Volume (3M)57.88K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees85
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,020,502
10 Day Avg. Volume46,440
30 Day Avg. Volume57,877
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-219.48
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Check-Cap Business Overview & Revenue Model
Company Description
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel....
How the Company Makes Money
Check-Cap generates revenue primarily through the development and commercialization of its C-Scan technology. Revenue streams include the sale of C-Scan systems and capsules to healthcare providers and institutions. The company may also earn incom...
Check-Cap Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -9.30M | 4.36M | -24.98M | -17.34M | -18.69M | -16.98M |
| Net Income | -25.15M | 4.14M | -25.15M | -17.57M | -19.11M | -17.20M |
Balance Sheet | ||||||
| Total Assets | 377.00K | 7.49M | 377.00K | 25.02M | 45.44M | 55.66M |
| Cash, Cash Equivalents and Short-Term Investments | 265.00K | 219.00K | 265.00K | 24.76M | 41.70M | 51.56M |
| Total Debt | 136.00K | 16.00K | 136.00K | 0.00 | 964.00K | 1.15M |
| Total Liabilities | 1.83M | 4.05M | 1.83M | 1.33M | 4.13M | 4.97M |
| Stockholders Equity | -1.45M | 3.44M | -1.45M | 23.69M | 41.31M | 50.69M |
Cash Flow | ||||||
| Free Cash Flow | -8.00K | -46.00K | -8.00M | -17.04M | -19.19M | -17.27M |
| Operating Cash Flow | -8.00K | -46.00K | -8.00M | -16.95M | -18.71M | -16.26M |
| Investing Cash Flow | -840.00 | 48.00K | -840.00K | 21.36M | -12.51M | -16.01M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 8.85M | 51.02M |
Check-Cap Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBAI, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for MBAI.
Check-Cap Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―